Cellular liaisons of natural killer lymphocytes in immunology and immunotherapy of cancer

Expert Opinion on Biological Therapy

Volumn 7, Issue 5, 2007, Pages 599-615

  Arina, Ainhoa ^b   Murillo, Oihana ^b   Dubrot, Juan ^b   Azpilikueta, Arantza ^b   Alfaro, Carlos ^b   Pérez Gracia, Jose L ^b   Bendandi, Maurizio ^b   Palencia, Belen ^b   Hervás Stubbs, Sandra ^b   Melero, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b NONE

Author keywords

Adaptive immunity; Cancer immunology; DC; Immunotherapy; NK cell; NKG2D

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; CD16 ANTIGEN; CYCLOPHOSPHAMIDE; FAS LIGAND; GRANZYME A; GRANZYME B; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 21; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 15; RECOMBINANT INTERLEUKIN 18; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL CONTACT; CELL INTERACTION; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOREGULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LEUKEMIA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MELANOMA; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; REVIEW; T LYMPHOCYTE; TARGET CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL COMMUNICATION; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIGANDS; MICE; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 34248167114     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.5.599     Document Type: Review

References (124)

1. WALLACE ME, SMYTH MJ: The role of natural killer cells in tumour control-effectors and regulators of adaptive immunity. Springer Semin. Immunopathol. (2005) 27(1):49-64.
2. WU J, LANIER LL: Natural killer cells and cancer. Adv. Cancer Res. (2003) 90:127-156.
3. RAULET DH: Natural killer cells. In: Fundamental Immunology. Paul WE (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (2003):365-391.
4. DI SANTO JP: Natural killer cell developmental pathways: a question of balance. Annu. Rev. Immunol. (2006) 24:257-286.
5. CHAN CW, CRAFTON E, FAN HN et al.: Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat. Med. (2006) 12(2):207-213. • See [6].
6. TAIEB J, CHAPUT N, MENARD C et al.: A novel dendritic cell subset involved in tumour immunosurveillance. Nat. Med. (2006) 12(2):214-219. • References [5] and [6] introduce IKDCs as a newly characterized immune subpopulation, different from NK cells and DCs, but sharing features of both cell types.
7. LOPEZ-BOTET M, PEREZ-VILLAR JJ, CARRETERO M et al.: Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immunol. Rev. (1997) 155:165-174.
8. MAK TW, SAUNDERS M: Bridging innate and adaptive immunity: NK, γδ T, and NKT cells. In: The Immune Response: Basic and Clinical Principles. Mak TW, Saunders M (Eds), Academic Press, San Diego, CA, USA (2005).
9. TAKEDA K, HAYAKAWA Y, SMYTH MJ et al.: Involvement of tumour necrosis factor-related apoptosis-inducing ligand in surveillance of tumour metastasis by liver natural killer cells. Nat. Med. (2001) 7(1):94-100.
10. CRETNEY E, TAKEDA K, YAGITA H et al.: Increased susceptibility to tumour initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. (2002) 168(3):1356-1361.
11. SMYTH MJ, TAKEDA K, HAYAKAWA Y et al.: Nature's TRAIL-on a path to cancer immunotherapy. Immunity (2003) 18(1):1-6.
12. SCREPANTI V, WALLIN RP, LJUNGGREN HG, GRANDIEN A: A cenrral role for death receptor-mediated apoptosis in the rejection of tumours by NK cells. J. Immunol. (2001) 167(4):2068-2073.
13. YOKOYAMA WM: Natural killer cells. In: Fundamental Immunology. Paul WE (Ed.), Lippincott Williams & Wilkins, Philadelphia, PA, USA (1999):575-603.
14. RODA JM, PARIHAR R, LEHMAN A et al.: Interleukin-21 enhances NK cell activation in tesponse to antibody-coated targers. J. Immunol. (2006) 177(1):120-129.
15. SMYTH MJ, HAYAKAWA Y, TAKEDA K, YAGITA H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer (2002) 2(11):850-861.
16. DUNN GP, KOEBEL CM, SCHREIBER RD: Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. (2006) 6(11):836-848.
17. KARRE K, LJUNGGREN HG, PIONTEK G, KIESSLING R: Selective rejection of H-2-deficient lymphoma varianrs suggests alternative immune defence strategy. Nature (1986) 319(6055):675-678.
18. MANDELBOIM O, LIEBERMAN N, LEV M et al.: Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature (2001) 409(6823):1055-1060.
19. LANIER LL: NK cell recognition. Annu. Rev. Immunol. (2005) 23:225-274.
20. LEE N, LLANO M, GARRETERO M et al.: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. USA (1998) 95(9):5199-5204.
21. ITO M, MARUYAMA T, SAITO N et al.: Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity. J. Exp. Med. (2006) 203(2):289-295.
22. ANFOSSI N, ANDRE P, GUIA S et al.: Human NK cell education by inhibitory receptors for MHC class I. Immunity (2006) 25(2):331-342.
23. BOTTINO C, MORETTA L, MORETTA A: NK cell acrivating receptors and tumour recognition in humans. Curr. Top. Microbiol. Immunol. (2006) 298:175-182.
24. RAULET DH: Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. (2003) 3(10):781-790.
25. FARAG SS, CALIGIURI MA: Human natural killer cell development and biology. Blood Rev. (2006) 20(3):123-137.
26. ARNON TI, LEV M, KATZ G et al.: Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur. J. Immunol. (2001) 31(9):2680-2689.
27. ARAMBURU J, BALBOA MA, RODRIGUEZ A et al.: Stimulation of IL-2-acrivated natural killer cells through the Kp43 surface antigen upregulates TNF-alpha production involving the LFA-1 integrin. J. Immunol. (1993) 151(7):3420-3429.
28. OSMAN MS, BURSHTYN DN, KANE KP: Activating Ly-49 receptors regulate LFA-1-mediated adhesion by NK cells. J. Immunol. (2007) 178(3):1261-1267.
29. BARBER DF, FAURE M, LONG EO: LFA-1 contributes an early signal for NK cell cytotoxicity. J. Immunol. (2004) 173(6):3653-3659.
30. MELERO I, BALBOA MA, ALONSO JL et al.: Signalling through the LFA-1 leucocyte integrin actively regulates intercellular adhesion and rumour necrosis factor-alpha production in natural killer cells. Eur. J. Immunol. (1993) 23(8):1859-1865.
31. KELLY JM, DARCY PK, MARKBY JL et al.: Induction of tumour-specific T cell memory by NK cell-mediated tumour rejection. Nat. Immunol. (2002) 3(1):83-90. •• One of the first experimental evidences of the ability of NK cells to mediate the establishment of adaptive immunity against tumours.
32. KELLY JM, TAKEDA K, DARCY PK, YAGITA H, SMYTH MJ: A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumour-expressing CD80 in vivo. J. Immunol. (2002) 168(9):4472-4479.
33. LEIBSON PJ: Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity (1997) 6(6):655-661.
34. KALINSKI P, MAILLIARD RB, GIERMASZ A et al.: Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin. Biol. Ther. (2005) 5(10):1303-1315.
35. DEGLI-ESPOSTI MA, SMYTH MJ: Close encounters of different kinds: dendritic cells and NK cells take centre stage. Nat. Rev. Immunol. (2005) 5(2):112-124.
36. FERLAZZO G, PACK M, THOMAS D et al.: Distinct toles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl. Acad. Sci. USA (2004) 101(47):16606- 16611.
37. GRANUCCI F, ZANONI I, PAVELKA N et al.: A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J. Exp. Med. (2004) 200(3):287-295.
38. BORG C, JALIL A, LADERACH D et al.: NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 104(10):3267-3275.
39. TERME M, TOMASELLO E, MARUYAMA K et al.: IL-4 confers NK stimulatory capacity to murine dendritic cells: a signalling pathway involving KARAP/DAP12-triggering receptor expressed on myeloid cell 2 molecules. J. Immunol. (2004) 172(10):5957-5966.
40. SEMINO C, ANGELINI G, POGGI A, RUBARTELLI A: NK/iDC interaction results in IL-18 secretion by DCs at the synaptic cleft followed by NK cell activation and release of the DC maturation factor HMGB1. Blood (2005) 106(2):609-616.
41. PICCIOLI D, SBRANA S, MELANDRI E, VALIANTE NM: Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. (2002) 195(3):335-341.
42. FERLAZZO G, TSANG ML, MORETTA L et al.: Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. (2002) 195(3):343- 351.
43. GEROSA F, BALDANI-GUERRA B, NISII C et al.: Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. (2002) 195(3):327-333.
44. POGGI A, CAROSIO R, SPAGGIARI GM et al.: NK cell activation by dendritic cells is dependent on LFA-1-mediated induction of calcium-calmodulin kinase II: inhibition by HIV-1 Tat C-terminal domain. J. Immunol. (2002) 168(1):95-101.
45. HAYAKAWA Y, SCREPANTI V, YAGITA H et al.: NK cell TRAIL eliminates immature dendritic cells in vivo and limits dendritic cell vaccination efficacy. J. Immunol. (2004) 172(1):123-129.
46. DELLA CHIESA M, VITALE M, CARLOMAGNO S et al.: The natutal killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A but lacking inhibitory killer Ig-like receptors. Eur. J. Immunol. (2003) 33(6):1657-1666.
47. PAN PY, GU P, LI Q et al.: Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J. Immunol. (2004) 172(8):4779-4789.
48. low targets are dissected and found to include the sequential activation of NK cells, DCs and CD8 T cells.
49. MARTIN-FONTECHA A, THOMSEN LL, BRETT S et al.: Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. (2004) 5(12):1260-1265. •• This work highlights the importance of NK cells as an early source of IFN-γ, necessary for the induction of Th1 responses.
50. STRBO N, OIZUMI S, SOTOSEK-TOKMADZIC V, PODACK ER: Perforin is required for innate and adaptive immunity induced by heat-shock protein gp96. Immunity (2003) 18(3):381-390.
51. WESTWOOD JA, KELLY JM, TANNER JE et al.: Cutting edge: novel priming of tumour-specific immunity by NKG2D-rriggered NK cell-mediated tumour rejection and Th1-independent CD4+ T cell pathway. J. Immunol. (2004) 172(2):757-761.
52. GROH V, RHINEHART R, SECRIST H et al.: Broad tumour-associated expression and recognition by tumour-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA (1999) 96(12):6879-6884.
53. DIEFENBACH A, JAMIESON AM, LIU SD, SHASTRI N, RAULET DH: Ligands for the murine NKG2D receptor: expression by tumour cells and activation of NK cells and macrophages. Nat. Immunol. (2000) 1(2):119-126.
54. UPSHAW JL, LEIBSON PJ: NKG2D-mediated activation of cytotoxic lymphocytes: unique signalling pathways and distinct functional outcomes. Semin. Immunol. (2006) 18(3):167-175.
55. REGUNATHAN J, CHEN Y, WANG D, MALARKANNAN S: NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors. Blood (2005) 105(1):233-240.
56. CARBONE E, NERI P, MESURACA M et al.: HLA class I, NKG2D, and natural cytoroxicity receptors regulate multiple myeloma cell recognition by natutal killer cells. Blood (2005) 105(1):251-258.
57. DIEFENBACH A, JENSEN ER, JAMIESON AM, RAULET DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (2001) 413(6852):165-171.
58. CERWENKA A, BARON JL, LANIER LL: Ectopic expression of rerinoic acid early inducible-1 gene (RAE-1) permirs narural killer cell-mediated rejection of a MHC class I-bearing tumour in vivo. Proc. Natl. Acad. Sci. USA (2001) 98(20):11521-11526. • References [57] and [58] are the first papers linking expression of NKG2D ligands and tumour rejection in vivo.
59. DIEFENBACH A, HSIA JK, HSIUNG MY, RAULET DH: A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumour immunity. Eur. J. Immunol. (2003) 33(2):381-391.
60. SMYTH MJ, SWANN J, CRETNEY E et al.: NKG2D function protects the host from tumour initiation. J. Exp. Med. (2005) 202(5):583-588.
61. CONEJO-GARCIA JR, BENENCIA F, COURREGES MC et al.: Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumour T cells. Cancer Res. (2004) 64(6):2175-2182.
62. GASSER S, RAULET DH: The DNA damage response arouses the immune system. Cancer Res. (2006) 66(8):3959-3962.
63. GIRARDI M, OPPENHEIM DE, STEELE CR et al.: Regulation of cutaneous malignancy by gammadelta T cells. Science (2001) 294(5542):605- 609.
64. GASSER S, ORSULIC S, BROWN EJ, RAULET DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature (2005) 436(7054):1186-1190. • Milestone article that finds the link between tumorigenesis and expression of NKG2D ligands.
65. ROUTES JM, RYAN S, MORRIS K et al.: Adenovirus serotype 5 E1A sensitizes tumour cells to NKG2D-dependent NK cell lysis and tumour rejection. J. Exp. Med. (2005) 202(11):1477-1482.
66. GROH V, WU J, YEE C, SPIES T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature (2002) 419(6908):734-738. • The first of a series of observations about the NKG2D system as a target for tumour manipulation conducive to immune evasion.
67. SALIH HR, RAMMENSEE HG, STEINLE A: Cutting edge: downregulation of MICA on human tumours by proteolytic shedding. J. Immunol. (2002) 169(8):4098-4102.
68. WALDHAUER I, STEINLE A: Proteolytic release of soluble UL16-binding protein 2 from tumour cells. Cancer Res. (2006) 66(5):2520-2526.
69. OGASAWARA K, HAMERMAN JA, HSIN H et al.: Impairmenr of NK cell function by NKG2D modulation in NOD mice. Immunity (2003) 18(1):41-51.
70. OPPENHEIM DE, ROBERTS SJ, CLARKE SL et al.: Susrained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumour immunosurveillance. Nat. Immunol. (2005) 6(9):928-937.
71. COUDERT JD, ZIMMER J, TOMASELLO E et al.: Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumour cells. Blood (2005) 106(5):1711-1717.
72. GROH V, BRUHL A, EL-GABALAWY H, NELSON JL, SPIES T: Stimulation of T cell autoreacrivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthtitis. Proc. Natl. Acad. Sci. USA (2003) 100(16):9452-9457.
73. GROH V, SMYTHE K, DAI Z, SPIES T: Fas ligand-mediated paracrine T cell regulation by the receptor NKG2D in rumour immunity. Nat. Immunol. (2006) 7(7):755-762.
74. KRIEGESKORTE AK, GEBHARDT FE, PORCELLINI S et al.: NKG2D-independent suppression of T cell proliferation by H60 and MICA. Proc. Natl. Acad. Sci. USA (2005) 102(33):11805-11810.
75. HAYAKAWA Y, SMYTH MJ: NKG2D and cytotoxic effector function in tumour immune surveillance. Semin. Immunol. (2006) 18(3):176-185.
76. WHITESIDE TL, HERBERMAN RB: Role of human narural killer cells in health and disease. Clin. Diagn. Lab. Immunol. (1994) 1(2):125-133.
77. MARGOLIN KA: Interleukin-2 in the treatment of renal cancer. Semin. Oncol. (2000) 27(2):194-203.
78. PHAN GQ, ATTIA P, STEINBERG SM, WHITE DE, ROSENBERG SA: Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. (2001) 19(15):3477-3482.
79. ROSENBERG SA, LOTZE MT, MUUL LM et al.: A progress reporr on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med. (1987) 316(15):889-897.
80. BUZIO C, ANDRULLI S, SANTI R et al.: Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer (2001) 92(9):2286-2296.
81. SILLA LM, WHITESIDE TL, BALL ED: The role of natural killer cells in the treatment of chronic myeloid leukaemia. J. Hematother. (1995) 4(4):269-279.
82. HARTMANN F, RENNER C, JUNG W et al.: Anti-CD16/CD30 bispecific antibody trearment for Hodgkins disease: role of infusion schedule and costimulation with cytokines. Clin. Cancer Res. (2001) 7(7):1873-1881.
83. YASUMURA S, LIN WC, HIRABAYASHI H et al.: Immunotherapy of liver metastases of human gastric carcinoma with IL-2-activated natural killer cells. Cancer Res. (1994) 54(14):3808-3816.
84. RUGGERI L, CAPANNI M, URBANI E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (2002) 295(5562):2097-2100. • This work supports haploidentical tranplantation in leukemia patients due to its high efficacy and clear advantages in the search for donors.
85. SHLOMCHIK WD, COUZENS MS, TANG CB et al.: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 285(5426):412-415.
86. DAVIES SM, RUGGIERI L, DEFOR T et al.: Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 100(10):3825-3827.
87. GIEBEL S, LOCATELLI F, LAMPARELLI T et al.: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood (2003) 102(3):814-819.
88. MILLER JS, SOIGNIER Y, PANOSKALTSIS-MORTARI A et al.: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105(8):3051-3057. • This study shows that haploidentical NK cells can persist and expand in vivo when they are infused following high-intensity immunosuppression regimes, and may have a role in the treatment of patients with hematological malignancies.
89. MELERO I, ARINA A, MURILLO O et al.: Immunogenic cell death and cross-priming are reaching the clinical immunotherapy arena. Clin. Cancer Res. (2006) 12(8):2385-2389.
90. MELERO I, HERVAS-STUBBS S, GLENNIE M, PARDOLL DM, CHEN L: Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer. (2007) 7(2):95-106.
91. MURILLO O, ARINA A, TIRAPU I et al.: Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. Clin. Cancer Res. (2003) 9(15):5454-5464.
92. GODFREY DI, KRONENBERG M: Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. (2004) 114(10):1379- 1388.
93. TERABE M, PARK JM, BERZOFSKY JA: Role of IL-13 in regulation of antitumour immunity and tumour growth. Cancer Immunol. Immunother. (2004) 53(2):79-85.
94. BENDELAC A, SAVAGE PB, TEYTON L: The biology of NKT cells. Annu. Rev. Immunol. (2006) 6:6.
95. SENTMAN CL, BARBER MA, BARBER A, ZHANG T: NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res. (2006) 95:249-292.
96. SMYTH MJ, CROWE NY, GODFREY DI: NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. (2001) 13(4):459-463.
97. ARGOV S, COCHRAN AJ, KARRE K, KLEIN GO, KLEIN G: Incidence and type of tumours induced in C57BL bg/bg mice and +/bg littermates by oral administration of DMBA. Int. J. Cancer (1981) 28(6):739-746.
98. GALLO-HENDRIKX E, COPPS J, PERCY D, CROY BA, WILDEMAN AG: Enhancement of pancreatic tumour metastasis in transgenic immunodeficient mice. Oncogene (1994) 9(10):2983-2990.
99. SHULTZ LD, SCHWEITZER PA, CHRISTIANSON SW et al.: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. (1995) 154(1):180-191.
100. KIM S, IIZUKA K, AGUILA HL, WEISSMAN IL, YOKOYAMA WM: In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc. Natl. Acad. Sci. USA (2000) 97(6):2731-2736.
101. VAN DEN BROEK ME, KAGI D, OSSENDORP F et al.: Decreased tumour surveillance in perforin-deficient mice. J. Exp. Med. (1996) 184(5):1781-1790.
102. KAPLAN DH, SHANKARAN V, DIGHE AS et al.: Demonstration of an interferon gamma-dependenr tumour surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA (1998) 95(13):7556-7561.
103. OWEN-SCHAUB LB, VAN GOLEN KL, HILL LL, PRICE JE: Fas and Fas ligand interactions suppress melanoma lung metastasis. J. Exp. Med. (1998) 188(9):1717-1723.
104. STREET SE, CRETNEY E, SMYTH MJ: Perforin and interferon-gamma activities independently control tumour initiation, growth, and metastasis. Blood (2001) 97(1):192-197.
105. SHANKARAN V, IKEDA H, BRUCE AT et al.: IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 410(6832):1107-1111.
106. SMYTH MJ, CRETNEY E, TAKEDA K et al.: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumour metastasis. J. Exp. Med. (2001) 193(6):661-670.
107. LJUNGGREN HG, KARRE K: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. (1985) 162(6):1745-1759.
108. GAO JX, LIU X, WEN J et al.: Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumour cells. Blood (2003) 102(13):4456-4463.
109. BRADLEY M, ZEYTUN A, RAFI-JANAJREH A, NAGARKATTI PS, NAGARKATTI M: Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumour cells. Blood (1998) 92(11):4248-4255.
110. KARP SE, FARBER A, SALO JC et al.: Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumour inhibition by IL-2 but not tumour necrosis factor. J. Immunol. (1993) 150(3):896-908.
111. ORTALDO JR, WINKLER-PICKETT RT, BERE EW JR et al.: In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells. J. Immunol. (2005) 175(2):693-699.
112. DIVINO CM, CHEN SH, YANG W et al.: Antitumour immunity induced by interleukin-12 gene therapy in a metastatic model of breast cancer is mediated by natural killer cells. Breast Cancer Res. Treat. (2000) 60(2):129-134.
113. RODRIGUEZ-CALVILLO M, DUARTE M, TIRAPU I et al.: Upregulation of natural killer cells functions underlies the efficacy of intratumourally injected dendritic cells engineered to produce interleukin-12. Exp. Hematol. (2002) 30(3):195-204.
114. CHAPOVAL AI, FULLER JA, KREMLEV SG, KAMDAR SJ, EVANS R: Combination chemotherapy and IL-15 administration induce permanent tumour regression in a mouse lung tumour model: NK and T cell-mediated effects antagonized by B cells. J. Immunol. (1998) 161(12):6977-6984.
115. MEAZZA R, LOLLINI PL, NANNI P et al.: Gene transfer of a secretable form of IL-15 in murine adenocarcinoma cells: effects on tumorigenicity, metastatic potential and immune response. Int. J. Cancer (2000) 87(4):574-581.
116. VERA M, RAZQUIN N, PRIETO J et al.: Intratumoural injection of dendritic cells transduced by an SV40-based vector expressing interleukin-15 induces curative immunity mediated by CD8+ T lymphocytes and NK cells. Mol. Ther. (2005) 12(5):950-959.
117. WANG G, TSCHOI M, SPOLSKI R et al.: In vivo antitumour activity of IL-21 mediated by natural killer cells. Cancer Res. (2003) 63(24):9016-9022.
118. TAKAKI R, HAYAKAWA Y, NELSON A et al.: IL-21 enhances tumour rejection through a NKG2D-dependent mechanism. J. Immunol. (2005) 175(4):2167-2173.
119. SMYTH MJ, WALLACE ME, NUTT SL et al.: Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. (2005) 201(12):1973-1985.
120. SMYTH MJ, SWANN J, KELLY JM et al.: NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J. Exp. Med. (2004) 200(10):1325-1335.
121. BRAUN SE, CHEN K, FOSTER RG et al.: The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumour rejection of murine breast cancer cells through NK cells. J. Immunol. (2000) 164(8):4025- 4031.
122. MELERO I, JOHNSTON JV, SHUFFORD WW, MITTLER RS, CHEN L: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumour immunity elicited by anti4-1BB monoclonal antibodies. Cell. Immunol. (1998) 190(2):167-172.
123. WILCOX RA, TAMADA K, STROME SE, CHEN L: Signalling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J. Immunol. (2002) 169(8):4230-4236.
124. ESPLUGUES E, VEGA-RAMOS J, CARTOIXA D et al.: Induction of tumour NK-cell immunity by anti-CD69 antibody therapy. Blood (2005) 105(11):4399-4406.